Compare · MEDP vs NRC
MEDP vs NRC
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and NRC Health (NRC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and NRC operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $17.18B, about 36.2x NRC ($474.2M).
- MEDP has hit the wire 5 times in the past 4 weeks while NRC has been quiet.
- MEDP has more recent analyst coverage (25 ratings vs 1 for NRC).
- Company
- Medpace Holdings Inc.
- NRC Health
- Price
- -
- -
- Market cap
- $17.18B
- $474.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 1
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
NRC Health
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
Latest MEDP
- SEC Form 10-Q filed by Medpace Holdings Inc.
- Medpace Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medpace Holdings, Inc. Reports Second Quarter 2026 Results
- Medpace downgraded by Robert W. Baird with a new price target
- Medpace downgraded by Jefferies with a new price target
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.27% to 10,352 units (SEC Form 4)
- Director Kraft Robert O. converted options into 33 shares, increasing direct ownership by 4% to 955 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.11% to 32,825 units (SEC Form 4)
- Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026
- New insider Hansman Brad W. claimed ownership of 697 shares (SEC Form 3)
Latest NRC
- NRC Health filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Berwick Donald M was granted 7,697 shares (SEC Form 4)
- Director Bhandari Parul was granted 7,697 shares (SEC Form 4)
- Director Lockhart Stephen H was granted 7,697 shares (SEC Form 4)
- Director Nunnelly John N was granted 7,697 shares, increasing direct ownership by 24% to 40,363 units (SEC Form 4)
- Director Wheeler Penny Ann was granted 7,697 shares (SEC Form 4)
- Citizens initiated coverage on National Research Corporation with a new price target
- NRC Health and Healthcare Experience Foundation Launch Strategic Partnership to Deepen Support for Improving Experience, Safety, and Workforce Engagement
- The Governance Institute Announces Blue Ribbon Committee on Health System Governance
- NRC Health Brings Ambient Listening With Agentic AI to the Front Lines of Leader Rounding